Search research articles
Contact Us
Filters
Showing results (1111-1120 of 1,174) with videos related to
Page
of 118
Sort By:
JCI Insight
|
June 9, 2026
Sustained Yap/Taz activation promotes aberrant alveolar epithelial cell differentiation and drives persistent fibrotic remodeling
Isabella P Gaona, A Scott McCall, Natalie M Geis, et al.
Biorxiv : the Preprint Server for Biology
|
July 10, 2023
Iron acquisition by a commensal bacterium modifies host nutritional immunity during <i>Salmonella</i> infection
Luisella Spiga, Ryan T Fansler, Yasiru R Perera, et al.
Biorxiv : the Preprint Server for Biology
|
August 12, 2025
Sustained Yap/Taz activation promotes aberrant alveolar epithelial cell differentiation and drives persistent fibrotic remodeling
Isabella P Gaona, A Scott McCall, Natalie M Geis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 30, 2026
Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial
Karim Fizazi, Matthew R Smith, Maha Hussain, et al.
The Journal of Urology
|
October 4, 2019
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data
E David Crawford, Przemyslaw W Twardowski, Raoul S Concepcion, et al.
Cell Host & Microbe
|
September 30, 2023
Iron acquisition by a commensal bacterium modifies host nutritional immunity during Salmonella infection
Luisella Spiga, Ryan T Fansler, Yasiru R Perera, et al.
Transplantation Proceedings
|
July 13, 2010
Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus
H Tedesco-Silva, V Duro Garcia, F L C Contieri, et al.
Cancer Medicine
|
November 11, 2024
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis
Motohide Uemura, Hiroaki Kikukawa, Yasuhiro Hashimoto, et al.
Nature Genetics
|
May 1, 1994
Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs
L L Green, M C Hardy, C E Maynard-Currie, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
September 8, 2011
Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917
James R Marshall, Catherine M Tangen, Wael A Sakr, et al.
Page
of 118
Search research articles
Search
Showing results (1111-1120 of 1,174) with videos related to
Sort By:
Page
of 118
JCI Insight
|
June 9, 2026
Sustained Yap/Taz activation promotes aberrant alveolar epithelial cell differentiation and drives persistent fibrotic remodeling
Isabella P Gaona, A Scott McCall, Natalie M Geis, et al.
Biorxiv : the Preprint Server for Biology
|
July 10, 2023
Iron acquisition by a commensal bacterium modifies host nutritional immunity during <i>Salmonella</i> infection
Luisella Spiga, Ryan T Fansler, Yasiru R Perera, et al.
Biorxiv : the Preprint Server for Biology
|
August 12, 2025
Sustained Yap/Taz activation promotes aberrant alveolar epithelial cell differentiation and drives persistent fibrotic remodeling
Isabella P Gaona, A Scott McCall, Natalie M Geis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 30, 2026
Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial
Karim Fizazi, Matthew R Smith, Maha Hussain, et al.
The Journal of Urology
|
October 4, 2019
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data
E David Crawford, Przemyslaw W Twardowski, Raoul S Concepcion, et al.
Cell Host & Microbe
|
September 30, 2023
Iron acquisition by a commensal bacterium modifies host nutritional immunity during Salmonella infection
Luisella Spiga, Ryan T Fansler, Yasiru R Perera, et al.
Transplantation Proceedings
|
July 13, 2010
Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus
H Tedesco-Silva, V Duro Garcia, F L C Contieri, et al.
Cancer Medicine
|
November 11, 2024
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis
Motohide Uemura, Hiroaki Kikukawa, Yasuhiro Hashimoto, et al.
Nature Genetics
|
May 1, 1994
Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs
L L Green, M C Hardy, C E Maynard-Currie, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
September 8, 2011
Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917
James R Marshall, Catherine M Tangen, Wael A Sakr, et al.
Page
of 118